Prognostic indicators & overall survival in men presenting with PSA levels greater than 1000ng/ml. by Palit, V & Gavin, Helen
University of Huddersfield Repository
Palit, V and Gavin, Helen
Prognostic indicators & overall survival in men presenting with PSA levels greater than 1000ng/ml.
Original Citation
Palit, V and Gavin, Helen (2010) Prognostic indicators & overall survival in men presenting with 
PSA levels greater than 1000ng/ml. In: British Association of Urological Surgeons Annual Meeting, 
21-24 June 2010, Manchester Central. (Submitted)
This version is available at http://eprints.hud.ac.uk/6780/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not-for-profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
Prognostic indicators & overall survival in men presenting with PSA levels greater
than 1000ng/ml.
Authors- Victor Palit, George Delves, Mike Kimuli , Karol Rowawski , Mike Stower &
Helen Gavin
Presentor- Victor Palit
Introduction- Men presenting with serum PSA above 400ng/ml have high incidence of
disease related morbidity with a poor overall survival.  However some men with very high
PSA (>1000ng/ml) have good hormone response with survival over 5 years.
The aim of this study was to determine the PSA response to hormonal therapy and
assess serum levels of alkaline phosphatise (SAP), & bone metastasis with overall
survival.
Material & Methods- In this retrospective study, 91 men with prostate cancer whose
PSA>1000ng/ml at initial presentation were identified between May 2004-August 2009.
Data regarding the treatment, clinical and biochemical response, survival were obtained
from case notes.
Results-
An  independent samples t-test to examine the effect of anti-androgenic therapy on
survival showed a significant difference (t = 5.874 p< 0.01, unequal variances) ,
suggesting a positive impact of therapy  Patients without metastasis achieved a larger fall
in PSA than those with metastasis, indicating that change in PSA levels may be a good
prognostic indicator. (F2,12 =4.79, p <0.05).
Chi-square test showed a significant association between SAP and metastasis status (
(2 = 6.526, p<0.05) suggesting SAP levels could be used as a predictor of metastasis.
Kaplan-Meier analysis showed a significant survival advantage with anti-androgenic
therapy. When metastasis is factored in as a stratifying function, the distinctions become
clearer .Adding the SAP levels, demonstrates a further impact.
Conclusion-Patients presenting with PSA> 1000ng/ml have poor survival .Change in
PSA levels, SAP & bone metastasis could be used as a prognostic indicator for
metastasis. SAP & bone metastasis could predict survival.
